Galena Biopharma to Present at the Immunotherapy Leaders' Forum 2012
Published: May 09, 2012
LAKE OSWEGO, Ore., May 9, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that Mark W. Schwartz, Ph.D., Executive Vice President and Chief Operating Officer, will give a presentation entitled, "Phase II Optimising NeuVax™ treatment for HER2 1+ and 2+ (HER2 negative) breast cancer patients: Identifying optimal patient populations for both meeting unmet medical need and optimising clinical trial success," at the Immunotherapy Leaders' Forum 2012 held in Barcelona, Spain. The presentation will take place on Friday, May 11, 2012 at 10:15 a.m. CEST at the Fira Palace, Barcelona, Spain. Today, Dr. Schwartz will also be featured on a panel entitled, "What characterisation work is really critical for immunotherapy R&D and how much are we doing just because we have the tools?"